CAMBRIDGE, Massachusetts, Oct 17 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a
gene-therapy company with a mission to develop cures for early-onset
life-threatening diseases, announced today that its company co-founder, Dr. Adi
Barzel, will present new data from its genome-editing platform during the 25th Annual European Society of
Gene & Cell Therapy (ESGCT) Congress in two presentations this
Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017,
at the bcc Berlin.
Dr. Barzel will present data in multiple animal models of disease
demonstrating the extended therapeutic potential of LogicBio’s proprietary
GeneRide™ platform technology. The GeneRide technology harnesses the natural
power of homologous recombination to enable precise, site-specific in
vivo genome editing to deliver therapeutic genetic material without
the use of vector-borne promoters or nucleases.
SOURCE : LogicBio
Therapeutics, Inc.
No comments:
Post a Comment